awmsg logo



darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®)


Reference No. 2418

Publication date:
06/03/2018


Appraisal information

darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) 800 mg/150 mg/200 mg/10 mg film-coated tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 10/01/2018
AWMSG meeting date: 14/02/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0418
Ratification by Welsh Government: 05/03/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).
AWMSG Secretariat Appraisal Report (ASAR)
Download